PT-141 (Bremelanotide) Sexual Health Therapy in Raleigh, NC

What is PT-141?

PT-141 is a synthetic cyclic peptide that acts at melanocortin receptors MC3R and MC4R located in the hypothalamus. Unlike PDE5 inhibitors such as sildenafil, which act on peripheral blood flow, PT-141 works centrally on neural pathways involved in sexual desire and arousal rather than acting on vascular smooth muscle.

PT-141 was developed as a refinement of Melanotan II. Bremelanotide received FDA approval in June 2019 under the brand name Vyleesi for the treatment of HSDD in premenopausal women. The FDA approval applies to that defined indication and population only.

FDA approval and off-label use

PT-141 (bremelanotide / Vyleesi) is FDA-approved only for treating hypoactive sexual desire disorder in premenopausal women. HSDD is defined as persistent low sexual desire that causes marked personal distress or interpersonal difficulty, not attributable to another medical or psychiatric condition, relationship problems, or medication side effects.

Use for any other indication or population—including men, postmenopausal women, or sexual dysfunction other than HSDD—is off-label. A RegenesisMD provider discusses the FDA-approved indication, the off-label status where relevant, available evidence, and individual health history before considering a protocol.

Clinical evidence

PT-141 is supported by Phase III clinical trial data. The RECONNECT and REVIVE trials enrolled 1,267 premenopausal women with generalized acquired HSDD. Both trials used the FDA-approved dose of 1.75 mg administered subcutaneously on demand, with efficacy measured using validated scales including the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS-DAO).

At week 24, bremelanotide produced statistically significant improvements in desire scores compared to placebo. The improvements were statistically meaningful on validated clinical scales; absolute effect sizes varied across individuals. A review published in PMC (Kingsberg et al., 2022) documented that bremelanotide demonstrated efficacy across multiple controlled clinical trials in women with HSDD, with improvements in both desire and distress measures.

Administration and safety considerations

The FDA-approved formulation is a subcutaneous injection administered approximately 45 minutes before anticipated sexual activity. The approved dose is 1.75 mg. No more than one dose should be taken in a 24-hour period, and no more than 8 doses per month per the FDA-approved protocol. At RegenesisMD, your provider determines the appropriate approach, including dose and administration protocol, based on each patient's individual health history, medications, and specific clinical picture.

The most commonly reported side effect is nausea, which is typically dose-related. Facial flushing, headache, and transient blood pressure changes have also been documented in clinical literature. Patients with cardiovascular conditions, uncontrolled hypertension, or high baseline cardiovascular risk should discuss these factors thoroughly with one of our RegenesisMD providers before initiating PT-141. Results are not guaranteed.

Consultation at RegenesisMD

Your provider conducts a full consultation including health history review before any PT-141 protocol is initiated. PT-141 is not appropriate for all patients, particularly those with certain cardiovascular conditions. Learn more about sexual health and rejuvenation services, the peptide therapy overview, and the RegenesisMD clinical team.

Frequently Asked Questions

What is PT-141 and is it FDA approved?

PT-141 (bremelanotide / Vyleesi) is FDA-approved specifically for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first FDA-approved centrally-acting agent for this indication. Use in men or postmenopausal women is off-label under physician supervision. Dr. Vaidya discusses the specific indication and any off-label use at consultation.

How is PT-141 different from Viagra or other sexual health medications?

PT-141 works through a fundamentally different mechanism. PDE5 inhibitors like sildenafil work on peripheral blood flow. PT-141 acts on melanocortin receptors MC3R and MC4R in the hypothalamus, which are central pathways involved in sexual desire and arousal. The two approaches target different aspects of sexual function. Dr. Vaidya reviews which approach is appropriate based on individual health history and goals.

What are the side effects of PT-141?

The most commonly reported side effect is nausea, which is typically dose-related. Facial flushing, headache, and transient blood pressure changes have also been documented in clinical literature. Patients with cardiovascular conditions, uncontrolled hypertension, or high baseline cardiovascular risk should discuss these factors thoroughly with one of our RegenesisMD providers before initiating PT-141.

Can men use PT-141?

The FDA approval for PT-141 is specific to premenopausal women with HSDD. Use in men is off-label. Off-label prescribing is legal and practiced in medicine when a physician determines it may support an individual patient's health goals. Dr. Vaidya reviews the available evidence and individual health profile before considering any off-label use.

How soon does PT-141 take effect?

The FDA-approved protocol calls for administration approximately 45 minutes before anticipated sexual activity. Individual timing response varies. Effects are generally reported within the 45 to 60 minute window after subcutaneous administration.

Medical disclaimer

PT-141 (bremelanotide / Vyleesi) is FDA-approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women only. Its use for any other indication or population is off-label and administered under the direct supervision of Dr. Bhavna Vaidya, MD. Individual results vary. This content is for educational purposes only. Schedule a consultation to discuss whether this therapy is appropriate for your health goals.